Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ken Herrmann

Showing results (391-400 of 721) with videos related to

Pageof 73
Sort By:
Oncotarget|December 13, 2017
Targeting CXCR4 with [<sup>68</sup>Ga]Pentixafor: a suitable theranostic approach in pleural mesothelioma?Constantin Lapa, Stefan Kircher, Andreas Schirbel, et al.
Plos One|July 18, 2015
Multiparametric MR and PET Imaging of Intratumoral Biological Heterogeneity in Patients with Metastatic Lung Cancer Using Voxel-by-Voxel AnalysisStephan Metz, Carl Ganter, Sylvie Lorenzen, et al.
Frontiers in Psychology|September 9, 2020
COVID-19-Related Fear and Health-Related Safety Behavior in Oncological PatientsVenja Musche, Alexander Bäuerle, Jasmin Steinbach, et al.
International Journal of Molecular Sciences|July 24, 2021
Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate CancerMagdalena Staniszewska, Pedro Fragoso Costa, Matthias Eiber, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 24, 2020
PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [<sup>177</sup>Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysisRobert Seifert, Katharina Kessel, Katrin Schlack, et al.
BMC Cancer|May 8, 2021
Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocolJeremie Calais, Shaojun Zhu, Nader Hirmas, et al.
Cancers|April 30, 2021
Predictive Factors for RAI-Refractory Disease and Short Overall Survival in PDTCDavid Kersting, Robert Seifert, Lukas Kessler, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 2, 2023
Efficacy and Safety of <sup>124</sup>I-MIBG Dosimetry-Guided High-Activity <sup>131</sup>I-MIBG Therapy of Advanced Pheochromocytoma or NeuroblastomaInes Maric, Manuel Weber, Andre Prochnow, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 12, 2024
EANM expert opinion: How can lessons from radiobiology be applied to the design of clinical trials? Part I: back to the basics of absorbed dose-response and threshold absorbed dosesJean-Pierre Pouget, Pablo Minguez Gabina, Ken Herrmann, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 4, 2018
Prospective comparison of <sup>18</sup>F-FDG PET/MRI and <sup>18</sup>F-FDG PET/CT for thoracic staging of non-small cell lung cancerJulian Kirchner, Lino M Sawicki, Felix Nensa, et al.
Pageof 73

Showing results (391-400 of 721) with videos related to

Sort By:
Pageof 73
Oncotarget|December 13, 2017
Targeting CXCR4 with [<sup>68</sup>Ga]Pentixafor: a suitable theranostic approach in pleural mesothelioma?Constantin Lapa, Stefan Kircher, Andreas Schirbel, et al.
Plos One|July 18, 2015
Multiparametric MR and PET Imaging of Intratumoral Biological Heterogeneity in Patients with Metastatic Lung Cancer Using Voxel-by-Voxel AnalysisStephan Metz, Carl Ganter, Sylvie Lorenzen, et al.
Frontiers in Psychology|September 9, 2020
COVID-19-Related Fear and Health-Related Safety Behavior in Oncological PatientsVenja Musche, Alexander Bäuerle, Jasmin Steinbach, et al.
International Journal of Molecular Sciences|July 24, 2021
Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate CancerMagdalena Staniszewska, Pedro Fragoso Costa, Matthias Eiber, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 24, 2020
PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [<sup>177</sup>Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysisRobert Seifert, Katharina Kessel, Katrin Schlack, et al.
BMC Cancer|May 8, 2021
Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocolJeremie Calais, Shaojun Zhu, Nader Hirmas, et al.
Cancers|April 30, 2021
Predictive Factors for RAI-Refractory Disease and Short Overall Survival in PDTCDavid Kersting, Robert Seifert, Lukas Kessler, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 2, 2023
Efficacy and Safety of <sup>124</sup>I-MIBG Dosimetry-Guided High-Activity <sup>131</sup>I-MIBG Therapy of Advanced Pheochromocytoma or NeuroblastomaInes Maric, Manuel Weber, Andre Prochnow, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 12, 2024
EANM expert opinion: How can lessons from radiobiology be applied to the design of clinical trials? Part I: back to the basics of absorbed dose-response and threshold absorbed dosesJean-Pierre Pouget, Pablo Minguez Gabina, Ken Herrmann, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 4, 2018
Prospective comparison of <sup>18</sup>F-FDG PET/MRI and <sup>18</sup>F-FDG PET/CT for thoracic staging of non-small cell lung cancerJulian Kirchner, Lino M Sawicki, Felix Nensa, et al.
Pageof 73